Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9291MR)

This product GTTS-WQ9291MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9291MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3803MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ15546MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ5417MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ9490MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ11508MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ3953MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ6147MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ5351MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW